Argitalpenak (232) FERNANDO PEREZ RUIZ argitalpenak

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759

2023

  1. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

    Arthritis and Rheumatology, Vol. 75, Núm. 5, pp. 816-825

  2. Mechanisms and rationale for uricase use in patients with gout

    Nature Reviews Rheumatology, Vol. 19, Núm. 10, pp. 640-649

  3. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set

    Seminars in Arthritis and Rheumatism, Vol. 60

  4. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  5. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Crystal-Associated Arthritis: Gout

    Synovial Fluid Analysis and the Evaluation of Patients with Arthritis (Springer International Publishing), pp. 91-100

  2. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

    Annals of the Rheumatic Diseases

  3. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

    Clinical Rheumatology, Vol. 41, Núm. 12, pp. 3817-3823

  4. Gout. What's up doc?

    Medicina Clinica, Vol. 158, Núm. 12, pp. 615-621

  5. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

  6. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  7. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  8. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

  9. Prévalence de la goutte dans la population générale en Espagne : une estimation du taux de cas non diagnostiqués

    Revue du Rhumatisme (Edition Francaise), Vol. 89, Núm. 4, pp. 389-395

2021

  1. Correction to: Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects (Journal of Human Genetics, (2021), 66, 2, (161-169), 10.1038/s10038-020-0821-z)

    Journal of Human Genetics

  2. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

  3. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  4. Serum uric acid and mortality thresholds among men and women in the Irish health system: A cohort study

    European Journal of Internal Medicine, Vol. 84, pp. 46-55

  5. Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects

    Journal of Human Genetics, Vol. 66, Núm. 2, pp. 161-169